ArteraAI, is testing a predictive artificial intelligence (AI) model for determining the benefit of androgen deprivation therapy (ADT) in prostate cancer patients.
In a study published by the the research showed not all patients require ADT and radiotherapy alone can be effective for many intermediate-risk patients. The study used deep learning methodologies and histopathology image data from over 5,000 subjects from 100 centres across the US and Canada in phase 3 randomised trials, which included long term follow ups.
The predictive AI 鈥榖iomarker鈥� developed by ArteraAI analyses large datasets comprising histopathology images and clinical information from diverse patient populations, including approximately 20% of African American patients. Notably, African American men have been underrepresented in previous prostate cancer trials, making up only 10.8% of participants
Prostate cancer has traditionally been treated using ADT in combination with radiotherapy. However, this approach often leads to various adverse effects, such as sexual dysfunction, and potential cardiac and neurological complications. By predicting ADT benefit through an AI-derived biomarker, clinicians could avoid subjecting patients to unnecessary treatment, alleviating the associated morbidity and financial burden.
Radiation oncologists and professors, Dr Daniel Spratt from University Hospitals Seidman Cancer Center and Dr Felix Feng from the University of California San Francisco, said ArteraAI’s discovery is potentially game-changing for prostate cancer treatment.
Dr Spratt said: 鈥淲ith the first-ever predictive biomarker of ADT benefit in prostate cancer, created with AI, we are able to further realise the ability to create a personalised approach for the treatment of cancer.鈥�
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDr Feng added: 鈥淭he validation of this biomarker by this highly credible and trusted publication is a milestone. We celebrate this achievement while also looking ahead to how we can build upon this evidence to continue transforming care for men diagnosed with localised prostate cancer.鈥�
